RT Journal Article SR Electronic T1 Hypertension Increases Cerebral 6-18F-Fluorodopa–Derived Radioactivity JF Journal of Nuclear Medicine JO J Nucl Med FD Society of Nuclear Medicine SP 1479 OP 1482 DO 10.2967/jnumed.109.062869 VO 50 IS 9 A1 David S. Goldstein A1 Courtney Holmes A1 LaToya Sewell A1 Irwin J. Kopin YR 2009 UL http://jnm.snmjournals.org/content/50/9/1479.abstract AB 6-18F-fluorodopa PET depicts the striatal dopaminergic lesion characterizing Parkinson disease (PD); however, striatal uptake of 6-18F-fluorodopa–derived radioactivity can be normal. Supine hypertension (SH) might increase 6-18F-fluorodopa uptake. Methods: We measured putamen, caudate, and occipital cortex 6-18F-fluorodopa–derived radioactivity and supine blood pressure in patients with PD + SH (systolic pressure ≥ 180 mm Hg, n = 8), patients with PD without SH (PD − SH, n = 19), patients with pure autonomic failure (n = 8), and controls (n = 16). Results: Peak putamen radioactivity correlated with supine systolic pressure across all subjects and among PD patients and was higher in PD + SH than in PD − SH (P = 0.01). Both subgroups had rapid fractional declines in radioactivity between the peak and late values (P < 0.0001, compared with controls). Arterial 6-18F-fluorodopa concentrations were similar in the compared groups. Conclusion: In PD, SH is associated with augmented striatal 6-18F-fluorodopa–derived radioactivity. Regardless of SH, retention of 6-18F-fluorodopa–derived radioactivity is markedly reduced. A model-independent approach can identify striatal dopaminergic denervation in PD.